Quantcast

Latest Interferon Stories

2014-10-22 16:28:46

FLINT, Mich., Oct. 22, 2014 /PRNewswire/ -- U.S. Food and Drug Administration (FDA) announced October 10, 2014 that Gilead Sciences Harvoni(® )(ledipasvir/sofosbuvir) product was approved for the treatment of chronic hepatitis C, genotype 1 infection in adults. Harvoni(®) is the first oral combination therapy approved for the treatment of hepatitis C and is also the first treatment regimen that does not require administration with pegylated interferon or ribavirin....

2014-10-21 04:21:53

MOSCOW, October 21, 2014 /PRNewswire/ -- Hepatera Ltd and its development partner MYR GmbH announced today the results of clinical trials investigating Myrcludex B in patients with chronic hepatitis B (HBV) and delta (HDV). The results suggest that Myrcludex B may become an option for treating hepatitis delta. With details to be presented at the AASLD meeting in Boston in November 2014, the trials also indicate positive results for the treatment of HBV infection. (Logo:...

2014-10-01 12:30:59

Data from 25 accepted abstracts include results from: NORTH CHICAGO, Ill., Oct. 1, 2014 /PRNewswire/ -- AbbVie (NYSE: ABBV) announced that data from its ongoing Phase 1 through Phase 3 hepatitis C clinical development programs will be presented at The Liver Meeting®, the Annual Meeting of the American Association for the Study of Liver Diseases (AASLD) in Boston, November 7-11, 2014. Abstracts will be presented highlighting results from AbbVie's investigational treatment combining three...

2014-09-28 23:02:11

MarketOptimizer.org adds “PharmaPoint: Hepatitis C Virus – Global Drug Forecast and Market Analysis to 2022 – Event-Driven Update” to its store. Hepatitis C Virus Market is expected to grow during the Forecast Period. Dallas, TX (PRWEB) September 28, 2014 The Hepatitis C Virus Market generated approximately $4.2 billion from global sales in 2012. Over the next 10 years, this market is expected to grow to reach $12.8 billion, with major growth occurring in the main Hepatitis C...

2014-09-17 08:29:05

DUBLIN, Sept. 17, 2014 /PRNewswire/ -- Research and Markets has announced the addition of the "Global Hepatitis C Market 2014-2018" report to their offering. http://photos.prnewswire.com/prnvar/20130307/600769 Hepatitis C is a liver disease caused by infection due to hepatitis C virus. Hepatitis C infection predominantly affects the liver; however, other parts of the body are also affected such as the brain and the digestive system. Hepatitis C virus is an RNA virus belonging to the family...

2014-09-16 08:32:04

HOUSTON, Sept. 16, 2014 /PRNewswire/ -- DNAtrix, Inc., experts in oncolytic virus development, today announced that the first patient was treated with the company's lead product, DNX-2401, a replication competent adenovirus plus gamma interferon in a randomized, multicenter, open-label Phase Ib study for patients with recurrent glioblastoma. "DNAtrix, in collaboration with leading neurosurgeons and neuro-oncologists in the US, is pleased to announce the initiation of our randomized...

2014-09-09 04:21:06

~Convening World's Leading Researchers in MS with a Program Covering all Aspects of Research Including Cause and Pathology, Genetics and Environmental Impact, Emerging Treatment Study Findings and Nervous System Repair BOSTON, Sept. 9, 2014 /PRNewswire/ -- On September 10-13 at the Hynes Convention Center in Boston, MA, ACTRIMS-ECTRIMS will host their joint triennial international meeting - MSBoston 2014, with over 8,000 participant from leading organizations in Europe, North America and...

2014-09-04 16:27:48

FLINT, Mich., Sept. 4, 2014 /PRNewswire/ -- Diplomat, the nation's largest independent specialty pharmacy, announced that it will distribute Plegridy(TM) (peginterferon beta-1a). Manufactured by Biogen Idec, Plegridy(TM) was approved on August 15, 2014 by the US Food and Drug Administration for the treatment of relapsing forms of multiple sclerosis (RMS). Plegridy is the only pegylated beta interferon approved for use in RMS and is dosed once every two weeks. Plegridy can be...

2014-09-02 08:31:32

ROCKLAND, Mass., Sept. 2, 2014 /PRNewswire/ -- EMD Serono, Inc., a subsidiary of Merck KGaA, Darmstadt, Germany, announced today that Drew Young has joined the company as Senior Vice President, Neurology and Immunology. In this capacity, he will be responsible for leading the strategic direction of the U.S. Neurology and Immunology franchise, including future products. http://photos.prnewswire.com/prnvar/20140902/141784 Bringing more than 20 years of experience leading global and...

2014-08-25 08:28:14

WOONSOCKET, R.I., Aug. 25, 2014 /PRNewswire/ -- MultiCell Technologies, Inc. (OTC: MCET) has been issued U.S. patent 8,809,290 covering novel drug compositions and platform technologies which redirect the immune system response to protect against highly virulent virus infection and cancer. These novel drug compositions consisting of noncoding doubled stranded RNA (dsRNA) molecules and recombinant immunoglobulin-peptide (IgP) molecules demonstrate unique immune stimulating activity,...


Latest Interferon Reference Libraries

0_9255b919f71eff1fd4202c1dbb1795d2
2011-01-12 15:49:29

Hepadnaviruses can cause liver infections in humans and animals. The two recognized genera are Genus Orthohepadnavirus and Genus Avihepadnavirus. It has a small genome of partially double-stranded, partially single stranded circular DNA. It is a group 7 virus that uses an RNA intermediate during replication. Most people who come into contact with the virus are able to clear the infection alone although some cannot and usually progress to fulminant hepatitis. It can cause sever liver...

More Articles (1 articles) »
Word of the Day
ramage
  • Boughs or branches.
  • Warbling of birds in trees.
Related